Failure of Immunotherapy—The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer

Immune checkpoint inhibitors (ICIs) have a huge impact on clinical treatment results in non-small cell lung cancer (NSCLC). Blocking antibodies targeting programmed cell death protein 1 (PD-1), programmed cell death protein ligand 1 (PD-L1) or CTLA-4 (cytotoxic T cell antigen 4) have been developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Błach, Justyna, Wojas-Krawczyk, Kamila, Nicoś, Marcin, Krawczyk, Paweł
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396490/
https://www.ncbi.nlm.nih.gov/pubmed/34445735
http://dx.doi.org/10.3390/ijms22169030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396490/
https://www.ncbi.nlm.nih.gov/pubmed/34445735
http://dx.doi.org/10.3390/ijms22169030

Ejemplares similares